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ABSTRACT
Insulin Treatment Increases Myocardial Ceramide Accumulation and
Disrupts Cardiometabolic Function
Aimee Elizabeth Hodson
Department of Physiology and Developmental Biology, BYU
Master of Science
Prevalence of diabetes, especially type 2 diabetes mellitus (T2DM) is increasing
worldwide. Millions of people are already affected by T2DM and estimates predict over half a
billion people will likely be suffering from the disease by 2030. T2DM is associated with an
increased risk of developing cardiovascular disease. Cardiovascular dysfunction is the leading
cause of mortality among type 2 diabetics.
Treatment for T2DM has changed over time. Though it was once known as insulin
independent, a large portion of type 2 diabetics are now treated with insulin injections.
However, type 2 diabetics treated with insulin are more likely to suffer from heart
complications. Due to this, we sought to determine the specific effect of insulin and insulininduced ceramide accrual on heart mitochondrial bioenergetics. To do so we used both in vitro
and in vivo models. H9c2 cardiomyocytes and adult male mice were treated with insulin with
or without the ceramide biosynthesis inhibitor myriocin. Mitochondrial bioenergetics were
determined in permeabilized cardiomyocytes and myocardium. In this study we demonstrate
that insulin induced ceramide accrual in both isolated cardiomyocytes and whole murine
myocardium. We further found that insulin treatment is sufficient to disrupt mitochondrial
respiration in both models. Inhibition of the ceramide accrual rescued mitochondrial respiration,
indicating that ceramide is necessary for the insulin-induced alterations in heart mitochondrial
respiration.
These results suggest that insulin has a role in the development of heart complications
associated with T2DM due to cardiomyocyte mitochondrial disruption. They also implicate
ceramide as a possible mediator in the development of insulin-related heart disorders.

Keywords:

type 2 diabetes, ceramide, mitochondria, hyperinsulinemia, insulin

ACKNOWLEDGEMENTS
I am grateful to the many people who have offered support, encouragement, and
guidance throughout my research and studies. I must first acknowledge the role of my family
for their constant encouragement. My parents’ excitement over new findings provided renewed
enthusiasm on my part. Thank you mom and dad for your love and support. I must acknowledge
my sister Melissa as well. Thank you for feeding me when I got too busy to cook for myself.
Thank you for keeping my days bright.
I would like to offer a special thanks to my mentor Benjamin Bikman. I started in his lab
as a Junior during my undergraduate studies, and he has been an incredible support over the
years. I am especially grateful for his example in application of learning to daily living. Thank
you Dr. Bikman for your enthusiasm, guidance, and example. You have truly enhanced my
experience at BYU and impacted my life.
I must express my gratitude to my graduate committee, Paul Reynolds and Brian Poole.
Your support has been invaluable. Thank you for your willingness to help me and for your
insight during my graduate experience.
Thank you as well to the members of the Bikman lab, especially Trevor Tippetts who
was my lab partner throughout this research. Thank you for being willing to sacrifice mice when
I got squeamish, for entertaining me with your music and stories, and for your friendship
throughout this project.
Finally, I am grateful to BYU and all the faculty and administrators who have taken part
in shaping my education both in my time as an undergraduate and graduate student. It has been
an incredible and rewarding experience.

TABLE OF CONTENTS
TITLE PAGE ................................................................................................................................. i
ABSTRACT................................................................................................................................... ii
ACKNOWLEDGEMENTS ..........................................................................................................iii
TABLE OF CONTENTS .............................................................................................................. iv
LIST OF FIGURES ...................................................................................................................... vi
CHAPTER 1: Introduction ............................................................................................................ 1
Type 2 Diabetes Mellitus ................................................................................................... 1
Cardiovascular Complications ........................................................................................... 2
Glucose and Insulin Research Paradigms .......................................................................... 3
Ceramide ............................................................................................................................ 4
Mitochondria ...................................................................................................................... 5
Summary of Research ........................................................................................................ 6
References .......................................................................................................................... 8
CHAPTER 2: Insulin Treatment Increases Myocardial Ceramide Accumulation and
Disrupts Mitochondrial Function ......................................................................... 14
Abstract ............................................................................................................................ 15
Background .......................................................................................................... 15
Methods................................................................................................................ 15
Results .................................................................................................................. 15
Conclusions .......................................................................................................... 16
Background ...................................................................................................................... 16
Methods............................................................................................................................ 17
Cell Culture .......................................................................................................... 17
Animals ................................................................................................................ 18
Lipid Isolation Analysis ............................................................................................... 18
iv

Protein Analysis ............................................................................................................19
Cell and Myocardium Permeabilization .............................................................. 19
Mitochondrial Respiration Protocol ..................................................................... 19
Statistics ............................................................................................................... 20
Results .............................................................................................................................. 20
Insulin Increases Cardiomyocyte Ceramide Accrual, Which Is
Necessary for Mitochondrial Disruption.............................................................. 20
Insulin Treatment Increases Body Mass and Causes Hyperinsulinemia
and Insulin Resistance in Mice ............................................................................ 21
Insulin Treatment in Mice Increases Muscle Ceramides and Alters
Mitochondrial Bioenergetics and Morphology .................................................... 22
Discussion ........................................................................................................................ 23
Conclusions ...................................................................................................................... 26
References ........................................................................................................................ 35
Chapter 3: General Discussion and Future Directions ................................................................. 41
References ........................................................................................................................ 44
CURRICULUM VITAE .............................................................................................................. 46

v

LIST OF FIGURES
Figure 2.1: Insulin Increases Ceramide in Cardiomyocytes ........................................................ 27
Figure 2.2: Ceramide Inhibition Prevents Insulin-Induced Mitochondrial Disruption. ............... 28
Figure 2.3: Insulin Treatment Affects Cardiomyocyte Mitochondrial Physiology ..................... 29
Figure 2.4: Insulin Injections Increase Body Mass, But Not Heart Mass in Mice....................... 30
Figure 2.5: Chronic Insulin Injections Increase Blood Insulin and Induce Glucose
and Insulin Intolerance ................................................................................................................. 31
Figure 2.6: Insulin Injection Increases Heart Ceramides ............................................................. 32
Figure 2.7: Chronic Insulin Injections Disrupt Myocardial Mitochondrial Function .................. 33
Figure 2.8: Chronic Insulin Injections Disrupt Myocardial Mitochondrial Function .................. 34

vi

CHAPTER 1: Introduction and Background
Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is currently a major public health problem, and
incidence is only increasing. In 2014 there were 29.1 million people with diabetes in the United
States. Another 86 million were pre-diabetic, and about 15-30% of pre-diabetics were expected
to develop T2DM over the next 5 years (Centers for Disease Control and Prevention, 2014).
Prediabetes is characterized by blood glucose levels that are higher than normal, but not high
enough for a full diagnosis as type 2 diabetes. This is due to the beginning stages of insulin
resistance, where insulin levels are abnormally high in order to keep glucose levels from
spinning out of control. There are no clearly visible symptoms associated with prediabetes.
Consequently, a large portion of those affected by prediabetes are unaware they have the
disease, are untreated, and are more likely to develop T2DM.
Estimates predict that in 2030 around 552 million persons worldwide will be affected by
T2DM (Whiting, Guariguata, Weil, & Shaw, 2011). T2DM is characterized by insulin
resistance, which causes the body to not use the insulin it produces effectively resulting in
higher than normal levels of glucose in the blood. It was previously known as non-insulin
dependent diabetes mellitus. However, as an estimated 29% of type 2 diabetics use insulin
injections in order to regulate their blood glucose levels, this term is no longer accurate (Centers
for Disease Control and Prevention, 2014). Another previous name for T2DM, adult-onset
diabetes, has also become irrelevant. Correlated with the trend of ever increasing childhood
obesity, prevalence of T2DM in children and adolescents has increased greatly over the past
decade (Amed, et al., 2010; Pinhas-Hamiel & Zitler, 2005). The dropping of these former
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names highlights the growing impact of T2DM as it affects people of all ages and the increasing
pervasiveness of insulin treatment.
Cardiovascular Complications
It has long been established that T2DM greatly increases the risk of cardiovascular
disease (Kannel & McGee, 1979). The two diseases share many common risk factors such as
dyslipidemia, insulin resistance, obesity, pro-inflammatory state, and pro-thrombotic states. The
presence of these common risk factors helps explain the correlation between T2DM and
cardiovascular dysfunction, however, it has been found that even independent of these risk
factors T2DM is associated with about a two-fold risk increase for cardiovascular disease (The
Emerging Risk Factors, 2010). Even when controlling for abnormal cholesterol levels, perhaps
the most commonly examined risk factor for cardiovascular disease, cardiovascular events have
been shown to increase with T2DM (van der Heijden, et al., 2013). Recent studies have also
found connections through shared regulator genes involved in the development of both T2DM
and cardiovascular disease (Chan, et al., 2014). The impact of these connections, and the search
for as of yet unknown pathways is currently a field of pronounced interest amongst researchers
examining T2DM.
Not only is T2DM connected with a greater risk of cardiovascular diseases, it increases
the risk of recurrence in those who have already experienced cardiovascular events. The
increased risk of repetition also escalates cardiovascular related mortality in T2DM (van der
Heijden, et al., 2013). It is therefore unsurprising that the major cause of mortality in persons
suffering from T2DM is cardiovascular disease (Sowers, Epstein, & Frohlich, 2001).
Due to the prevalence of T2DM, the high correlation between cardiovascular
dysfunction and T2DM, the increased risk of recurrence, and the impact of cardiovascular
2

disease on T2DM-related mortality there is considerable importance in gaining a deeper
understanding concerning how these two diseases are connected.
Glucose and Insulin Research Paradigms
A large percentage of past research has focused on the impact of high glucose levels as
the link between heart dysfunction and T2DM (Fuentes-Antrás, et al., 2015; Laakso, 1999;
Matheus, et al., 2013; Schmidt, Yan, Wautier, & Stern, 1999). Through this paradigm of
thought many important discoveries concerning glucose-related mechanisms have been made.
Poor glycemic control has been linked to inflammation, receptor for advanced glycation
endproducts (RAGE activation, and possible disruption of mitochondrial function (Nelson, et
al., 2015a; Schmidt, et al., 1999; Tilton, et al., 1995). It seems possible, however, that there
may be an equally, if not more, impactful role for high insulin levels on cardiovascular health in
T2DM (Mandavia, Aroor, DeMarco, & Sowers, 2013; Pories & Dohm, 2012). These findings
are especially relevant as insulin injections have become a more common medication for
controlling glucose levels in T2DM. While such therapies are successful in lowering blood
glucose levels in T2DM, they also lead to an increase in mortality (The Action to Control
Cardiovascular Risk in Diabetes Study, 2008). It is therefore expedient that further
investigations be made to determine the impacts of high insulin levels associated with T2DM on
cardiovascular health.
Recent research has suggested that while intensive glucose control may lead to a
reduction in microvascular complications, it is not as effective in preventing cardiovascular
complications (Laakso, 1999). Other glucose control studies have shown that intensive-therapy,
which often includes insulin injections, may result in a decrease in cardiovascular events, but no
corresponding increase in patient survival (Hayward, et al., 2015). This is not to say that
3

glucose control is unimportant in T2DM treatment. Higher risk of cardiovascular events has
been seen in conjunction with poor glycemic control due to lack of treatment or delay of
treatment (Green, et al., 2015; Paul, Klein, Thorsted, Wolden, & Khunti, 2015). It has also been
shown that patients with better controlled glucose experienced a significant reduction in
cardiovascular events survival (Holman, Paul, Bethel, Matthews, & Neil, 2008). However, the
research is still contradictory. There are contrasting studies showing no significant improvement
in cardiovascular dysfunction with better controlled glucose (Prato, 2009; Skyler, et al., 2009).
Due to the inconsistency of the data, some researchers have begun looking for new
treatment options with more concrete results. One new direction which has shown promise is
the use of medications that control hyperglycemia without increasing insulin to reduce the risk
of cardiovascular dysfunction in T2DM (Green, et al., 2015). These hopeful results offer further
credence to the importance of insulin in the etiology of T2DM, and offers an area for future
research.
Ceramide
Ceramide is a sphingolipid made of a combination of sphingoid base backbone,
sphingosine, and a fatty acid. As denoted by their name, given in reference to the mysterious
Sphinx, the function of sphingolipids was unknown for many years. Today, these lipids are still
under investigation, but roles in cell differentiation, cell membranes, signaling pathways that
mediate cell growth, and cell death have been elucidated (Merrill Jr, et al., 1997). Ceramide in
particular has been implicated in cellular stress responses and mediation of several
inflammatory factors such as TNF-α and interleukin-1 (Merrill Jr, et al., 1997).
There are two pathways through which ceramide is synthesized: the de novo pathway
and a recycling pathway. In the de novo pathway several enzymes -- including serine
4

palmitoyltransferase, 3-ketosphingosine reductase, ceramide synthase, and ceramide desaturase
– are involved in converting palimtoyl-CoA to ceramide (Pralhada Rao, et al., 2013). Ceramide
can also be formed through the hydrolysis of more complex sphingolipids, or sphingolipid
recycling. This recycling process is an important part of lipid homeostasis (Pralhada Rao, et al.,
2013).
In previous studies it has been found that increasing insulin levels also leads to an
accumulation of ceramide in skeletal muscle (Hansen, et al., 2014). As understanding of the
role ceramide plays has improved, it has become more and more apparent that the accumulation
of ceramide is linked with the pathogenesis of several diseases, including Alzheimer’s, obesity,
metabolic syndrome, type 1 diabetes mellitus, and T2DM (Filippov, et al., 2012; Galadari,
Rahman, Pallichankandy, Galadari, & Thayyullathil, 2013; X. Li, Becker, & Zhang, 2010;
Yuyama, Mitsutake, & Igarashi, 2014). Ceramides have also recently been increasingly
implicated as playing a role in the development of cardiovascular diseases (Di Paola, Cocco, &
Lorusso, 2000; X. Li, et al., 2010; Park, et al., 2008; Zhang, et al., 2012). The relationship
between ceramide and these diseases, as well as the accumulation of ceramide in the presence of
high insulin, implicates a possible role for ceramide as a mediator for cardiovascular
dysfunction in type 2 diabetics. It has been postulated that one method through which ceramides
are negatively impacting cardiac function is through increasing mitochondrial fission (Smith, et
al., 2013).
Mitochondria
Mature cardiomyocytes have a high metabolic demand, and are therefore highly
oxidative cells. Most of the energy required for cardiomyocyte contractions is supplied through
the oxidative phosphorylation of the mitochondria (Lemieux & Hoppel, 2009). A disruption in
5

the function of cardiac mitochondria can lead to heart failure (Holmgren, et al., 2003;
Lesnefsky, Moghaddas, Tandler, Kerner, & Hoppel, 2001). Mitochondrial function depends
greatly on its morphology and connectivity. In the fusion state mitochondria form a reticular
network and have increased rates of respiration. In contrast, the fission state is characterized by
a disintegration of mitochondrial connectivity and a decrease in respiratory capacity (Ishihara,
Jofuku, Eura, & Mihara, 2003). T2DM is associated with an increase in mitochondrial fission
(P. Li, et al., 2012), and mitochondrial fission has been connected with an increase in cardiac
dysfunction (Pennanen, et al., 2014).
Due to the crucial role of healthy mitochondria to cardiac health, as well as the
pathological implications of dysfunctional mitochondria, it is important to understand the
factors which affect mitochondrial form and function. Better understanding the connection
between T2DM, high insulin, and cardiac dysfunction could lead to better prevention of T2DM
mortality and is an important area of research.
In view of the evidence implicating a role for insulin in the etiology of cardiac
complications, especially through ceramide mediated mitochondrial disruption, the aim of this
study is to better elucidate the role of insulin in cardiac dysfunction and investigate the
possibility of ceramide as an intermediate in the pathway of insulin induced disruption of
cardiac metabolic activity.
Summary of Research
Previous research conducted in the BYU obesity and metabolism lab has centered on the
sphingolipid ceramide and its effects in a wide array of circumstances. The research has
reinforced the notion of ceramide as a key player in mediating several of the pathological
consequences of obesity and type 2 diabetes mellitus. Our lab has previously demonstrated that
6

insulin increases ceramides in skeletal muscle (Hansen, et al., 2014). It was shown in our lab
that ceramides are secreted from A549 lung cells after exposure to cigarette smoke (Thatcher et
al 2014). The lab built on this study in order to show that myocardiocytes incubated with the
medium taken from cigarette smoke-exposed lung cells results in a pronounced inhibition of
myocardial mitochondrial respiration. This effect could be attenuated through ceramide
inhibition (Tippetts, et al., 2014).
These findings complement previous results generated in our lab regarding ceramide and
mitochondrial function. As described previously, morphology is extremely important in
mitochondrial function. Healthy mitochondria are in the fusion morphology, meaning they form
a reticular network throughout the cell (Ishihara, Jofuku, Eura, & Mihara, 2003). In contrast, our
lab has found a correlation between ceramides and the disruption of this fusion state. This
disruption is known as mitochondrial fission, which means the reticular network is decreased,
mitochondrion become more separated from one another, and the mitochondrial respiration is
reduced. Our lab found this process stimulates mitochondrial fission through dynamin related
protein 1 (Smith, et al., 2013).
Following the previously seen effects of insulin in increasing ceramide accumulation in
skeletal muscle, and the effects of ceramide on the heart, we hypothesized that high insulin
would produce a similar result in cardiomyocytes, and this presence of ceramides would then
disrupt mitochondrial activity.
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Abstract

Background
States of hyperinsulinemia, particularly insulin resistance and type 2 diabetes mellitus,
are becoming remarkably common, with roughly half a billion people likely to suffer from the
disorder within the next 15 years. Along with this rise has been an associated increased burden
of cardiovascular disease. Considering type 2 diabetics treated with insulin are more likely to
suffer from heart complications, we sought to determine the specific effect of insulin on
ceramide-dependent cardiometabolic risk factors, including insulin resistance and altered heart
mitochondrial physiology.
Methods
H9c2 cardiomyocytes and adult mice were treated with insulin with or without myriocin
to inhibit ceramide biosynthesis. Insulin and glucose changes were tracked throughout the study
and mitochondrial bioenergetics was determined in permeabilized cardiomyocytes and
myocardium.
Results
Herein, we demonstrate that insulin is sufficient to disrupt heart mitochondrial
respiration in both isolated cardiomyocytes and whole myocardium, possibly by increasing
mitochondrial fission. Further, insulin increases ceramide accrual in a time-dependent manner,
which is necessary for insulin-induced alterations in heart mitochondrial respiration and insulin
resistance.
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Conclusions
Collectively, these observations have two implications. First, they indicate a pathological
role of insulin in heart complications stemming from mitochondrial disruption. Second, they
identify ceramide as a possible mediator of insulin-related heart disorders.
Background
We have known for decades that type 2 diabetes mellitus diabetes (T2DM) increases the
risk of heart disease [1]. Indeed, the observation is so common that this phenomenon is referred
to as “diabetic heart disease”, bringing attention to the fact that cardiovascular complications are
the most common cause of mortality in those suffering with T2DM [2,3]. Considering the
increasing incidence of T2DM worldwide [4], and the remarkable number of undiagnosed
cases, at least in early stages [5], understanding the nature of the relationship between these two
pathologies may prevent heart disease and prolong healthy living among those with T2DM.
Reflective of the prevailing understanding of the etiology of T2DM, a great deal of
research efforts have focused on glucose and glycemic control as the causal factors between
T2DM and heart disease [6–10]. This focus has elucidated several glucose-related mechanisms,
such as the reduction of glucose to sorbitol [11], and especially, the formation of advanced
glycation end-products (AGE) and activation of its receptor (RAGE) [12–14]. Moreover,
whether a consequence of RAGE activation or a distinct mechanism, hyperglycemia is known
to induce inflammation [15]. Similarly, poor glycemic control may disrupt mitochondrial
function and increase production of reactive oxygen species [16].
However, while the focus on glucose as a mediating mechanism linking T2DM to
cardiovascular complications has yielded valuable insight, it nevertheless ignores what may be
at least an equally relevant etiological factor of T2DM etiology—insulin. Pories and Dohm
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recently posited that excess insulin, not glucose, is the essential factor in T2DM onset [17], a
position supported by considerable evidence [18]. T2DM is a progressive spectrum of insulin
resistance, with overt T2DM representing a state where insulin secretion, despite being
elevated, is no longer sufficient to control blood glucose. As some have recommended a
paradigm shift from looking at diabetes as a consequence of hyperinsulinemia rather than
hyperglycemia, we are prompted to explore the causal relationship between T2DM and heart
disease in a similar light.
Previous reports have observed a role for insulin in the etiology of cardiovascular
complications [19]. Importantly, insulin therapy, despite adequately controlling blood glucose,
has been shown to increase mortality in T2DM [20]. Similar to glucose-induced mechanisms
(e.g., AGE formation, etc.), insulin has distinct downstream mediators; one mediator may be the
sphingolipid ceramide. Ceramides are increasingly recognized as an injurious mediator of heart
pathologies [21–25] and we have recently found that insulin increases ceramide biosynthesis
and accrual in skeletal muscle [26, 27]. In light of the evidence suggesting a role for insulin in
the etiology of heart complications, the purpose of these experiments was to determine the
effect of insulin on heart ceramides, as well as possible ceramide-induced alterations in
mitochondrial function.
Methods
Cell Culture
H9c2 cardiomyocytes were maintained in DMEM +10 % FBS. For differentiation into
myotubes, cells were grown to confluency and the medium was replaced with DMEM +10 %
horse serum (Invitrogen, Grand Island, NY). Myotubes were used for experiments on day 3 of
differentiation. Cells were treated with insulin (50 nM; Actrapid; Novo Nordisk, Plainsboro,
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NJ) and myriocin (10 µM; Sigma), an inhibitor of serine palmitoyltransferase, at the times
indicated.
Animals
Sixteen-week-old male C57Bl/6 mice were separated into one of four groups (six per
group) to receive morning injections of saline (PBS), insulin (daily; 0.75 U/kg/BW; Actrapid;
Novo Nordisk, Plainsboro, NJ), myriocin (thrice weekly; 0.3 mg/kg; Sigma) or both for 28 days
with free access to water and chow (Harlan 8604) throughout the length of the study. After the
28-d treatment, mice underwent intraperitoneal glucose (G7021; Sigma-Aldrich, St. Louis, MO)
and insulin (Actrapid; Novo Nordisk, Plainsboro, NJ) tolerance tests. For both tests, mice were
fasted for 6 h and received an injection of either glucose (1 g/kg body wt) or insulin (0.75 U/kg
body wt). These are doses that are above the typical rate of insulin treatment in type 2 diabetics
(0.5 U/kg) [28]. Plasma glucose (Bayer Contour glucose meter), insulin (ELISA; Crystal Chem
Inc.), and adiponectin (Crystal Chem Inc.) levels were determined. Studies were conducted in
accordance with the principles and procedures outlined in the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by the IACUC
(Institutional Animal Care and Use Committee) at Brigham Young University.
Lipid Isolation Analysis
Lipids were extracted and quantified as described previously [29]. Briefly, lipids were
isolated with chloroform–methanol (1:2), and after addition of water, the organic phase was
collected and dried. After resuspension, lipids were quantified using a shotgun lipidomics
technique on a Thermo Scientific LTQ Orbitrap XL mass spectrometer.
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Protein Analysis
Cell and tissue proteins were analyzed via western blot as described previously [29].
Cell and Myocardium Permeabilization
For cells, H9c2 cardiomyocytes were detached in culture dishes with 0.05 % trypsin–
EDTA (Sigma) and growth medium was added to the culture. Contents were transferred to a
tube and centrifuged for 10 min at 1000×g at RT. After removal of supernatant, cells were lifted
in MiR05 [0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lactobionate, 20 mM taurine, 10 mM
KH2PO4, 20 mM HEPES, 110 mM sucrose, and g/l BSA (Sigma; A3803) adjusted to pH 7.1]
plus 1 mg/ml digitonin and gently rocked at RT for 5 min before centrifugation at 1000×gfor
5 min. After discarding supernatant, cells were then suspended in 2.2 ml warm MiR05 and
transferred to chambers in the O2K (Oroboros Instruments, Innsbruck, Austria). Following
respiration protocol (outlined below), cells were removed from the chambers and used for
protein quantification. For myocardial mitochondrial respiration, left ventricle was quickly
removed from euthanized mice and immediately placed in ice-cold buffer X (60 mM K-MES,
35 mM KCl, 7.23 mM K2EGTA, 2.77 mM CaK2EGTA, 20 mM imidazole, 20 mM tuarine,
5.7 mM ATP, 15 mM PCr, 6.56 mM MgCl2–6H2O, pH 7.1) and trimmed of connective tissue.
Small fiber bundles were prepared and gently separated along their longitudinal axis under a
surgical scope (Olympus, ST) to 1–2 mg. Bundles were then transferred to a tube with chilled
buffer X and 50 μg/ml saponin and rocked at 4 °C for 30 min, then washed in buffer Z
(105 mM K-MES, 30 mM KCl, 10 mM KH2PO4, 5 mM MgCl2–6H2O, 0.5 mg/ml BSA, pH 7.1)
at 4 °C for at least 15 min. Samples were then blotted dry and weighed.
Mitochondrial Respiration Protocol
High-resolution O2 consumption was determined at 37 °C in permeabilized cells and
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fiber bundles using the Oroboros O2 K Oxygraph with MiR05 respiration buffer. Before
addition of sample into respiration chambers, a baseline respiration rate was determined. After
addition of sample, the chambers were hyperoxygenated to ~300 nmol/ml. Following this,
respiration was determined by all or parts of the following substrate-uncoupler-inhibitortitration (SUIT) protocol: electron flow through complex I was supported by
glutamate + malate (10 and 2 mM, respectively) to determine leak oxygen consumption
(GM L ). Following stabilization, ADP (2.5 mM) was added to determine oxidative
phosphorylation capacity (GM D ). Succinate was added (GMS D ) for complex I + II electron
flow into the Q-junction. To determine full electron transport system capacity in cells over
oxidative phosphorylation, the chemical uncoupler carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP) was added (0.05 μM, followed by 0.025 μM steps until maximal O2
flux was reached). Mitochondrial membrane integrity was tested in all experiments by
adding cytochrome c (not shown; 10 μM). Lastly, residual oxygen consumption was measured
by adding antimycin A (2.5 μM) to block complex III action, effectively stopping any electron
flow, which provides a baseline rate of respiration.
Statistics
Data are presented as the mean ± SEM. Data were compared by ANOVA with Tukey’s
post hoc analysis (Graphpad Prism; La Jolla, CA). Significance was set at p < 0.05.
Results
Insulin Increases Cardiomyocyte Ceramide Accrual, Which is Necessary for
Mitochondrial Disruption
We observed a significant time-dependent increase in ceramide accrual in
cardiomyocytes with insulin treatment (Fig. 2.1a), which was supported with an increase in
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heart levels of serine palmitoyltransferase 2 (SPT2) and dihydroceramides desaturase 1 (Des1)
with insulin treatment (Fig. 2.1b) at 24 h. Whereas 1 h of insulin had no effect on ceramides, 6 h
of treatment roughly doubled ceramide levels, a level maintained, but not significantly
increased, at 12 and 24 h. With previous mitochondrial-specific effects of ceramides in mind
[23, 25], we next determined whether this ceramide accrual had any effect on cardiomyocyte
mitochondrial bioenergetics. Insulin altered mitochondrial respiration in a contrasting and timedependent manner. At 1 h of insulin treatment, respiration was increased in cardiomyocytes, but
significantly decreased at 6 and 24 h (Fig. 2.2a). Insulin-induced alterations in respiration were
also evident in the reduced respiratory control ratio, an overall indication of mitochondrial
health [30], at longer time points (Fig. 2.2b). Moreover, distinct function of complex IImediated respiration, defined as the CII factor, revealed acutely increased (at 1 h) then decreased
(at 6 and 24 h) respiration rates (Fig. 2.2c). Overall, uncoupling control ratio, calculated as
maximal uncoupled respiration by FCCP relative to ADP-stimulated state, was comparable
among all conditions (Fig. 2.2d). Importantly, inhibition of ceramide accrual with myriocin
abolished the insulin-induced decrement in respiration (Fig. 2.2a–c).
Additionally, we found that insulin altered mitochondrial morphology, appearing to
increase mitochondrial fission (Fig. 2.3a), which was prevented with ceramide inhibition. Drp1
levels were similar among all treatments (Fig. 2.3b). Further, 1 h of insulin treatment was
associated with an increase in mitochondrial complex III levels, but this was lost with 24 h
(Fig. 2.3c).

Insulin Treatment Increases Body Mass and Causes Hyperinsulinemia and Insulin
Resistance in Mice
To determine whether an in vivo correlate exists to substantiate our in vitro findings,
we injected adult male mice (16 week old) with insulin daily (0.75 mg/kg) for 28 days. At the
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conclusion of the 28 days treatment period, mice injected with insulin (INS) gained
significantly more body mass than PBS-injected mice (Fig. 2.4a); however, those injected with
insulin (daily) and myriocin (thrice weekly; INS + MYR) did not gain such mass. Moreover,
those injected with myriocin alone (MYR) weighed less than PBS-injected mice. While heart
mass tended to increase with INS injection (Fig. 4b; P = 0.072), the change was not significant,
and was even less remarkable when controlled for by body mass (Fig. 2.4c). INS-injected mice
also had higher fasting insulin (Fig. 2.5a), but not glucose (Fig. 2.5b) over the course of the
treatment. Further, INS treatment caused compromised glucose and insulin tolerance (Fig. 2.5a,
b, respectively), but not with ceramide inhibition.

Insulin Treatment in Mice Increases Muscle Ceramides and Alters Mitochondrial Bioenergetics
and Morphology
28 days of insulin elicited a roughly two-fold increase in myocardial ceramide content
(Fig. 2.6a), though myriocin co-treatment prevented this effect. This effect was supported with
an increase in heart SPT2 levels (Fig. 2.6b). Moreover, blood adiponectin was robustly inhibited
with INS and moderately protected with MYR injections (Fig. 2.6c). Functionally, the increased
ceramide accrual had a demonstrable and deleterious effect on myocardial mitochondrial
respiration. In particular, overall respiration and RCR was reduced with INS treatment (Fig.
2.7a, b), though CII factor was not significantly changed (Fig. 2.7c). Lastly, we found that
myocardialmitochondria were smaller with INS treatment compared with all other conditions
(Fig. 2.8a, b), though this was not reflected in any change in levels of mitochondrial complex
proteins (Fig. 2.8c). This effect may be a result of INS-induced increased Drp1 levels
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in the heart (Fig. 2.8d).
Discussion
Type 2 diabetes carries an increased risk of developing a surprising and increasing
number of pathologies. Multiples lines of evidence reveal its hand in diseases stemming from
cognitive [31], reproductive [32], musculoskeletal [33], and cardiovascular disorders [34].
However, type 2 diabetes is typified by two key characteristics—hyperglycemia and
hyperinsulinemia [35, 36]—and while the disease has historically been defined by blood
glucose levels, insulin may be a more sensitive and relevant diagnostic [37]. Indeed, a very
recent study found that higher insulin exposure in type 2 diabetics is associated with a threefold
increase in cardiovascular events [38]. Herein, we demonstrate that chronic insulin injections
exert a time-specific and ceramide-dependent effect on cardiometabolic function, including
insulin resistance and heart mitochondrial changes.
These studies provide additional insight into the etiology of type 2 diabetes-related heart
complications. In particular, these results suggest that insulin is an important pathogenic
mediator and highlight the need to regularly measure insulin when evaluating heart disease risk.
Our findings of insulin impacting mitochondrial physiology are not new—Parra et al. [39]
found that insulin increased mitochondrial respiration. However, while we tended to see an
overall dampening effect of insulin on mitochondrial respiration, a notable difference between
our studies is the length of time; this previous report used a 3-h incubation, while we used
several time points in our in vitro model. Indeed, our data corroborate those of Parra et al. [39]
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when we analyzed mitochondrial respiration at 1 h, but not at periods over 6 h. Combined with
our observations following a 4-week insulin treatment in mice, these data collectively suggest
the clinical relevance of prolonged increases in insulin.
In mice, we found that prolonged insulin treatment resulted in reduced glucose and
insulin tolerance, suggesting that insulin alone, independent of other variables, is capable of
inducing insulin resistance. This observation corroborates evidence from several previous
reports in humans and rodents wherein hyperinsulinemia from endogenous (e.g., insulinoma)
[40] and exogenous (e.g., injections) [26, 41, 42] sources causes insulin resistance. This insulindesensitizing effect of prolonged hyperinsulinemia is likely at least partially mediated via
ceramide accrual [26]. While it is possible that the insulin-resistant state caused by the insulin
treatment in our study exerts some confounding effect on altering heart mitochondrial function
independent of insulin-induced heart ceramide accrual, we nonetheless consider this an apparent
feature of the prolonged hyperinsulinemia. Nevertheless, insulin resistance per se, in the
absence of the often-accompanying hyperinsulinemia, may be the responsible lesion.
In light of the observations by Dohm and Pories [17], who implicate hyperinsulinemia in
the etiology of T2DM, we submit an alternative hypothesis as to the origins of diabetic heart
disease that should be considered. As opposed to heart disease being a consequence of the
potentially harmful milieu associated with T2DM, perhaps heart disease and T2DM are each
consequences of one pathology—hyperinsulinemia. Such a theory is supported by multiple
reports that implicate insulin alone in the etiology of both heart disease [43–45] and T2DM
[46, 47]. Over two decades ago, Haffner et al. [48] wondered about the role of insulin and
queried whether heart disease started before diabetes onset, when insulin, but not glucose, is
elevated. Their results add to the body of evidence that insulin is an important etiological factor
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in heart disease. A significant strength of measuring insulin is that it is elevated earlier than
glucose in the progression to frank T2DM [46, 47] allowing not only an earlier diagnosis, but
also an earlier, and thus more effective, intervention. Collectively, these observations emphasize
the need to measure insulin in routine health screenings.
Altogether, these results highlight the pathogenicity of hyperinsulinemia on
cardiometabolic function, including insulin resistance and heart mitochondria. These findings
are corroborated by recent work by Marciniak et al. [49] who found reduced cardiac
mitochondrial function in a mouse model of type 2 diabetes, with concomitant
hyperinsulinemia. Interestingly, cardiac mitochondrial function was largely unaffected in the
streptozotocin-induced model of type 1 diabetes, which strengthens the insulin-centric paradigm
of altered cardiometabolic health with type 2 diabetes. Another finding from Marciniak et al.
[49] was that adiponectin was reduced in their model of type 2 diabetes, but not type 1, which is
a common finding in humans [35]. Considering the actions of adiponectin signaling on
ceramide metabolism [50] and cardiovascular function [51], the reduced adiponectin that
accompanies most insulin-resistant conditions may provide additional explanation into the
increased heart ceramide accrual and reduced adiponectin we observed in our model of directly
induced hyperinsulinemia [52].
The purpose of these studies was to explore the effect of insulin in altering
cardiometabolic function, with a focus on two main components: insulin resistance and heart
mitochondrial dynamics and physiology. However, while our findings shed light on the role of
insulin in cardiometabolic pathologies, they nevertheless fall short of allowing firm conclusions
concerning cardiovascular health. Thus, a significant weakness that will need to be addressed in
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future studies is the lack of analyses to determine a functional impairment with the heart in this
same context.
Conclusions
Our data suggest two potential therapeutic strategies for mitigating the heart disease
burden associated with states of elevated insulin (e.g., pre-diabetes or T2DM). First, drugs to
induce insulin sensitization (e.g., metformin) should take priority over drugs that induce insulin
secretion (e.g., sulfonylurea), which is associated with a reduction [53] and increase [54–56] in
heart disease risk, respectively. Second, ceramide inhibition may prove to be an effective
deterrent to heart disease risk in various conditions, including hyperinsulinemia, as mounting
evidence suggests inhibition of ceramide biosynthesis is effective at protecting cardiovascular
health [57–59].
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Figure 2.1: Insulin Increases Ceramide in Cardiomyocytes. H9C2 cardiomyocytes were treated with
insulin (INS; 50 nM) with or without myriocin (MYR; 10 μM), an inhibitor of ceramide biosynthesis, for
the times indicated (n = 6). Following treatment time, lipids were isolated for analysis of sphingolipids
via LCMS (a; n = 6) and protein levels of ceramide biosynthetic enzymes determined (b; n = 4).
*P < 0.05 for INS vs. other treatments.

27

Figure 2.2: Ceramide Inhibition Prevents Insulin-Induced Mitochondrial Disruption. H9C2
cardiomyocytes were treated with insulin (INS; 50 nM) with or without myriocin (MYR; 10 μM), an
inhibitor of ceramide biosynthesis, for the times indicated (n = 6). To measure mitochondrial respiration
(a), cells were treated with: GM L , Glutamate (10 mM) + Malate (2 mM); GM D : + ADP (2.5 mM);
GMS D , + Succinate (10 mM); GMS F , + FCCP (0.05 μM). Respiratory control ratio (RCR; b), Complex
II Factor (c), and uncoupling control ratio (UCR; d) were determined by the analysis indicated. *P < 0.05
for condition vs. control (PBS).
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Figure 2.3: Insulin Treatment Affects Cardiomyocyte Mitochondrial Physiology. H9C2 cardiomyocytes
were treated with insulin (INS; 50 nM) with or without myriocin (MYR; 10 μM), an inhibitor of
ceramide biosynthesis, for the times indicated. Following treatment, cells were imaged to determine
mitochondrial morphology (a; n = 3), and analyzed for Drp1 protein levels (b; n = 4), and mitochondrial
complex proteins (c; n = 4). *P < 0.05 for INS vs. PBS; #P < 0.05 for INS + MYR vs. INS alone.
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Figure 2.4: Insulin Injections Increase Body Mass, but not Heart Mass in Mice. 16-week-old male mice
received injections of PBS (daily), insulin (INS; daily; 0.75 mg/kg), myriocin (MYR, thrice weekly;
3 mg/kg), or INS + MYR for 28 d. Body mass increased in the INS-treated mice only (a; n = 6). Heart
mass was measured in all mice (b, c; n = 6). *P < 0.05 for INS vs. PBS;#P < 0.05 for INS + MYR vs.
INS alone.
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Figure 2.5: Chronic Insulin Injections Increase Blood Insulin and Induce Glucose and Insulin
Intolerance. 16-week-old male mice received injections of PBS (daily), insulin (INS; daily; 0.75 mg/kg),
myriocin (MYR, thrice weekly; 3 mg/kg), or INS + MYR. Blood insulin (a) and glucose (b) was tracked
weekly. At the conclusion of the study, IP glucose (c) and insulin (d) tolerance tests were performed.
*P < 0.05 for INS vs. PBS; #P < 0.05 for INS + MYR vs. INS alone.
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Figure 2.6: Insulin Injection Increases Heart Ceramides. 16-week-old male mice received injections of
PBS (daily), insulin (INS; daily; 0.75 mg/kg), myriocin (MYR, thrice weekly; 3 mg/kg), or INS + MYR.
INS treatment increased myocardial ceramide accrual (a) and SPT2 (b). Serum adiponectin was also
measured (c). *P < 0.05 for condition vs. PBS. #P < 0.05 for INS + MYR vs. INS alone.
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Figure 2.7: Chronic Insulin Injections Disrupt Mitochondrial Function. 16-week-old male mice received
injections of PBS (daily), insulin (INS; daily; 0.75 mg/kg), myriocin (MYR, thrice weekly; 3 mg/kg), or
INS + MYR. Mitochondrial assessments were determined in permeabilized (saponin, 50 µg/ml)
myocardium. To measure mitochondrial respiration (a), samples were treated with: GM L , Glutamate
(10 mM) + Malate (2 mM); GM D , + ADP (2.5 mM); GMS D , + Succinate (10 mM). Respiratory control
ratio (RCR; b) and Complex II Factor (c) were determined by the analysis indicated. *P < 0.05 for
condition vs. PBS.
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Figure 2.8: Chronic Insulin Injections Disrupt Myocardial Mitochondrial Function. 16-week-old male
mice received injections of PBS (daily), insulin (INS; daily; 0.75 mg/kg), myriocin (MYR, thrice
weekly; 3 mg/kg), or INS + MYR. Heart samples were processed for imaging via electron microscopy
(a) and quantified based on average greatest mitochondrial diameter (b; n = 3). A portion of samples was
used to probe for mitochondrial complexes (c; n = 3) and Drp1 (D; n = 3). *P < 0.05 for condition vs.
PBS.
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CHAPTER 3: General Discussion and Future Directions
Our data from the preceding chapter enhances the findings of previous studies
implicating ceramide as an intermediate between hyperinsulinemia and cardiovascular disease.
It builds on the earlier study done by our lab showing ceramide accrual in cardiomyocytes
contributes to a decrease in mitochondrial respiration and increase in mitochondrial fission, both
of which indicate mitochondrial dysfunction (Smith, et al., 2013). Mitochondrial dysfunction
has been linked to cardiac dysfunction (Lesnefsky, et al., 2001). Indeed, the highly oxidative
character of cardiomyocytes makes mitochondrial function essential for normally functioning
cardiomyocytes. In chapter 2 we found that insulin leads to an increase in mitochondrial
dysfunction and ceramide is necessary for those observed detrimental effects. Taken in context
with these previous studies this provides strong evidence of a link between high insulin levels
and cardiac dysfunction.
The first point examined by this study was confirming that high insulin levels will
increase ceramide accrual in cardiac tissue. Investigations of insulin and ceramide interactions
have become increasingly popular over recent years. However, ceramides have proved
somewhat difficult to investigate as there are no membrane receptors for ceramides and
ceramides with long chains of fatty acids cannot pass through the cell plasma membrane. This
leaves two possible means of study, stimulate cells to increase intracellular content or use short
chain ceramides that can diffuse across membranes (Górski, 2012). Intracellular ceramide
content can be manipulated by affecting the physiological conditions which regulate amounts of
de novo synthesis. For example, increased obesity, cigarette smoke, and gene manipulation have
all been used to stimulate ceramide accumulation (Alayoubi, et al., 2013; Haus, et al., 2009;
Nelson, et al., 2015b; Mikayla O. Thatcher, et al., 2014). Our lab has previously shown that
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high insulin levels also cause ceramide accrual in skeletal muscle (Hansen, et al., 2014). In the
current study we expanded on this finding by using insulin to increase ceramide accrual in the
cardiomyocytes.
We then explored how ceramide accumulation impacted mitochondrial function in the
cardiomyocytes. It has previously found that ceramide negatively influences mitochondrial
function in a wide variety of cells (Smith, et al., 2013; M. O. Thatcher, et al., 2014; Tippetts, et
al., 2014; Wang, et al., 2009). In this study we found that increased insulin levels lead to
mitochondrial dysfunction and that ceramide is necessary for this to occur. Prior findings
showed an increase, rather than a decrease, in mitochondrial respiration after insulin treatment
(Parra, et al., 2014). At first this finding may seem to be at odds with our data; however, the
Parra et. al. study used a 3-hour incubation period. In our study we used several different time
periods: 1-hour, 6-hour, and 24-hour treatments. The 1-hour study showed an increase in
respiration rates, while longer incubation periods resulted in a decrease in mitochondrial
respiration.
As mitochondrial function has previously been shown to be linked to mitochondrial
morphology (Westermann, 2012) we also looked at insulin effects on mitochondrial
morphology. Our findings suggest an increase in mitochondrial fission following insulin
treatment, results which can be reversed through ceramide inhibition. Mitochondrial fission and
decreased mitochondrial function have been linked to increased risk of heart failure (Chen &
Knowlton, 2011; Knowlton, Chen, & Malik, 2014; Marín-García, Akhmedov, & Moe, 2012;
Ong & Hausenloy, 2010). While our current study did not measure heart failure risk, it is
reasonable to hypothesize the observed changes in mitochondrial function and morphology
would have detrimental effects on cardiac health. Future research into the exact effects of high
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insulin and consequent mitochondrial morphology changes on cardiac function would be
important in better understanding the physiological effects of high insulin.
Historically T2DM has been mainly defined through blood glucose levels. This
viewpoint has provided important information relative to the etiology of T2DM (Matheus, et al.,
2013; Nelson, et al., 2015a; Schmidt, et al., 1999). The results from this study suggest that
insulin, as well as glucose, is an important pathogenic mediator in T2DM. We found that
chronic insulin injections exert a time-specific effect on insulin resistance and glucose tolerance,
and this effect is dependent on ceramide. These results indicate that insulin alone is able to
induce insulin resistance. Insulin induced insulin resistance has been found previously as well
(Hansen, et al., 2014; Prato, et al.). Our results corroborate the findings in these previous
studies. We also found the insulin resistance development could be mitigated through ceramide
inhibition. This implicates ceramide accrual as an intermediate in the development of insulin
resistance from increased insulin levels.
Taken together these findings point towards the possibility that heart disease may not be
a side effect of the pathological effects of T2DM. Instead, it seems possible both T2DM and
heart disease are developed concurrently due to the effects of hyperinsulinemia developed in
those who are insulin resistant. It also indicates a potential reason why insulin injections lead to
increased mortality in T2DM through cardiac dysfunction. These results suggest increased
investigation is needed to better characterize the relationship between high insulin levels,
ceramide accrual, and cardiac dysfunction. Such studies may help lead to better treatment
options for T2DM.
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